Development Doctors Pharma Companies Trials 
pharmaphorum
JANUARY 24, 2022
The UK scientists that ran one of the largest trials of experimental COVID-19 drugs have formed a non-profit company that will apply the methodology to other disease areas – with $6.8 ” Those trials also need to be large, involve a diverse range of individuals, and able to be run at reduced cost, said Landray. .
pharmaphorum
MARCH 12, 2021
COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. Speakers at the NIHR’s recent virtual event for the pharma industry discussed best practices for bringing patient insights into research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 30, 2022
Josh Sackman, president and co-founder of AppliedVR, and Web Sun, president and co-founder of Komodo Health, relay how their newly formed collaboration reshapes the clinical trial process by using data, helping to cut costs and allowing for evaluation of broader patient populations. . Distinct offerings.
Pharmaceutical Technology
MARCH 17, 2023
At the same time, experts are saying developers in the field need to double down on securing clinical data to allow for its continued maturation. Companies are testing the use of digital platforms along with pharmacological treatments. Securing reimbursement for digital therapeutics also continues to impede its uptake.
World of DTC Marketing
MARCH 11, 2022
But do doctors trust the system? consumers’ trust in pharma is low, despite the industry’s contributions to ending the pandemic: Only 15% of U.S. consumers say they trust pharma companies more than they did before the COVID-19 pandemic, according to Accenture’s 2021 survey.
pharmaphorum
APRIL 8, 2021
COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to do to ensure this progress is not lost, said speakers at WIRED Health 2021, including the CEOs of BioNTech and BenevolentAI. . BioNTech seeks “new kind of pharma company”.
pharmaphorum
DECEMBER 21, 2021
During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals. The potential to leverage genomic data.
Expert insights. Personalized for you.
93 
Let's personalize your content